145 related articles for article (PubMed ID: 16082417)
1. In vivo assessment of the cutaneous bioavailability of topically applied maxacalcitol.
Ikeda Y; Hirata K; Kano S; Yanagihara H; Takahara J; Kondo K; Umemura K
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):305-10. PubMed ID: 16082417
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous pharmacokinetics of topically applied maxacalcitol ointment and lotion.
Umemura K; Ikeda Y; Kondo K; Hirata K; Amagishi H; Ishihama Y; Tokura Y
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):289-94. PubMed ID: 18541125
[TBL] [Abstract][Full Text] [Related]
3. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator.
Barker JN; Ashton RE; Marks R; Harris RI; Berth-Jones J
Br J Dermatol; 1999 Aug; 141(2):274-8. PubMed ID: 10468799
[TBL] [Abstract][Full Text] [Related]
4. Receptor microscopic autoradiography for the study of percutaneous absorption, in vivo skin penetration, and cellular-intercellular deposition.
Hayakawa N; Kubota N; Imai N; Stumpf WE
J Pharmacol Toxicol Methods; 2004; 50(2):131-7. PubMed ID: 15385087
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of a supplementary cyclosporin administration with a topical application of maxacalcitol ointment for patients with moderate psoriasis vulgaris.
Abe M; Syuto T; Hasegawa M; Yokoyama Y; Ishikawa O
J Dermatol; 2009 Apr; 36(4):197-201. PubMed ID: 19348657
[TBL] [Abstract][Full Text] [Related]
6. Assessment of topical bioavailability in vivo: the importance of stratum corneum thickness.
Kalia YN; Alberti I; Naik A; Guy RH
Skin Pharmacol Appl Skin Physiol; 2001; 14 Suppl 1():82-6. PubMed ID: 11509911
[TBL] [Abstract][Full Text] [Related]
7. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab.
Karakawa M; Komine M; Kishimoto M; Maki N; Matsumoto A; Sugai J; Ohtsuki M
J Dermatol; 2016 Nov; 43(11):1354-1357. PubMed ID: 27450634
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients.
Imagawa I; Suzuki H
J Dermatol; 2007 Apr; 34(4):264-6. PubMed ID: 17352726
[No Abstract] [Full Text] [Related]
9. Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study.
Draelos ZD
Cutis; 2015 Aug; 96(2):135-41. PubMed ID: 26367752
[TBL] [Abstract][Full Text] [Related]
10. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial.
Umezawa Y; Nakagawa H; Tamaki K
J Dermatol; 2016 Mar; 43(3):288-93. PubMed ID: 26282062
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
Wiedersberg S; Naik A; Leopold CS; Guy RH
Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
[TBL] [Abstract][Full Text] [Related]
12. Clinical effect of vitamin D3 analogues is not inactivated by subsequent UV exposure.
Adachi Y; Uchida N; Matsuo T; Horio T
Photodermatol Photoimmunol Photomed; 2008 Feb; 24(1):16-8. PubMed ID: 18201352
[TBL] [Abstract][Full Text] [Related]
13. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis.
Lahfa M; Mrowietz U; Koenig M; Simon JC
Eur J Dermatol; 2003; 13(3):261-5. PubMed ID: 12804986
[TBL] [Abstract][Full Text] [Related]
14. Treatment of psoriasis vulgaris with narrow-band UVB and topical Maxacalcitol.
Takekoshi T; Asahina A; Komine M; Tamaki K
Acta Derm Venereol; 2006; 86(4):375-6. PubMed ID: 16874435
[No Abstract] [Full Text] [Related]
15. Analysis of in vitro skin permeation of 22-oxacalcitriol from ointments based on a two- or three-layer diffusion model considering diffusivity in a vehicle.
Yamaguchi K; Mitsui T; Aso Y; Sugibayashi K
Int J Pharm; 2007 May; 336(2):310-8. PubMed ID: 17240092
[TBL] [Abstract][Full Text] [Related]
16. Infantile acropustulosis treated successfully with topical maxacalcitol.
Kimura M; Higuchi T; Yoshida M
Acta Derm Venereol; 2011 May; 91(3):363-4. PubMed ID: 21336473
[No Abstract] [Full Text] [Related]
17. In vitro-in vivo correlation study for the dermatopharmacokinetics of terbinafine hydrochloride topical cream.
Saeheng S; Nosoongnoen W; Varothai S; Sathirakul K
Drug Dev Ind Pharm; 2013 Sep; 39(9):1372-7. PubMed ID: 23057672
[TBL] [Abstract][Full Text] [Related]
18. Progress in methodologies for evaluating bioequivalence of topical formulations.
Shah VP
Am J Clin Dermatol; 2001; 2(5):275-80. PubMed ID: 11721645
[TBL] [Abstract][Full Text] [Related]
19. Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy.
Abramovits W
J Drugs Dermatol; 2009 Aug; 8(8 Suppl):s17-22. PubMed ID: 19702032
[TBL] [Abstract][Full Text] [Related]
20. The tape stripping procedure--evaluation of some critical parameters.
Lademann J; Jacobi U; Surber C; Weigmann HJ; Fluhr JW
Eur J Pharm Biopharm; 2009 Jun; 72(2):317-23. PubMed ID: 18775778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
